Generics Bulletin Explains: After Humira Biosimilars, Will It Be Groundhog Day For Stelara?
Could Familiar Product Profile And Settlements Framework Mean A Rerun Of Adalimumab?
With ustekinumab biosimilars set to launch in Europe imminently and in the US early next year, the off-patent industry may be wondering whether it will be in for a rerun of its experiences with competition on Humira – or whether the landscape has changed sufficiently to allow for different pricing and uptake trends. Generics Bulletin looks at the expectations of a host of industry leaders.
